2019-2020 Session
Change SessionS.252
An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
- Sponsor(s)
- Last Recorded Action
- Senate 9/11/2020 - Recommitted to Committee on Health and Welfare on motion of Senator Ashe
Bill/Resolution Text
NOTE: to print information that appears on a tab within the bill page, use the Print link on that tab.
An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Detailed Status
Regular Session 2019-2020
| Body | Date | Journal | Calendar | Location | Full Status |
|---|
An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Roll Call History
Regular Session 2019-2020
| Body | Date | Journal | Location | Full Status |
|---|
Although procedurally bills and resolutions are assigned to only one committee at a time, other committees may review the bill or resolution. This page contains results from both the assigned committee as well as other committees.
An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Committee Meetings
Regular Session 2019-2020
| Meeting Date | Committee |
|---|
An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Meeting Full List
Regular Session 2019-2020
Friday, January 17, 2020
- Committee(s):
- Senate Committee on Health and Welfare
- -
-
S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Walk-through
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Tuesday, February 4, 2020
- Committee(s):
- Senate Committee on Health and Welfare
- 10:45 AM
-
S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Walk-through
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Friday, February 14, 2020
- Committee(s):
- Senate Committee on Health and Welfare
- 9:00 AM
-
S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Daniel Weiss, Professor of Medicine, Professor of Cell and Molecular Biology, University of Vermont
Cindy Bruzzese, Director, Vermont Ethics Network
Jessa Barnard, Executive Director, Vermont Medical Society
Lauren Hibbert, Director, Office of Professional Regulation, Office of the Secretary of State
Charity Clark, Chief of Staff, Attorney General's Office
Shayla Livingston, Public Health Policy Advisor, Department of Health
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Tuesday, February 18, 2020
- Committee(s):
- Senate Committee on Health and Welfare
- 10:30 AM
-
S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Mark-up
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Cindy Bruzzese, Director, Vermont Ethics Network
Lauren Hibbert, Director, Office of Professional Regulation, Office of the Secretary of State
David Herlihy, Director of Hospital Licensing, Department of Health, Executive Director, Vermont Board of Medical Practice
Tuesday, February 25, 2020
- Committee(s):
- Senate Committee on Health and Welfare
- 10:30 AM
-
S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Discussion
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Friday, February 28, 2020
- Committee(s):
- Senate Committee on Health and Welfare
- 10:00 AM
-
S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Discussion and possible vote
Jonathon Fenton, Vermont Regenerative Medicine
Charity Clark, Chief of Staff, Attorney General's Office
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Jessa Barnard, Executive Director, Vermont Medical Society
- 11:15 AM
-
S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Discussion
Tuesday, March 10, 2020
- Committee(s):
- Senate Committee on Health and Welfare
- -
-
S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Discussion and possible vote
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
David Herlihy, Director of Hospital Licensing, Department of Health, Executive Director, Vermont Board of Medical Practice
Friday, March 13, 2020
- Committee(s):
- Senate Committee on Health and Welfare
- 8:50 AM
-
S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Discussion
Thursday, August 27, 2020
- Committee(s):
- Senate Committee on Health and Welfare
- 11:20 AM
-
S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Walk through, committee discussion
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Committee Documents
An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Witnesses Who Testified
Regular Session 2019-2020
Senate Committee on Health and Welfare
- Jessa Barnard, Executive Director, Vermont Medical Society
- Cindy Bruzzese, Director, Vermont Ethics Network
- Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
- Charity Clark, Chief of Staff, Attorney General's Office
- Jonathon Fenton, Vermont Regenerative Medicine
- David Herlihy, Director of Hospital Licensing, Department of Health, Executive Director, Vermont Board of Medical Practice
- Lauren Hibbert, Director, Office of Professional Regulation, Office of the Secretary of State
- Shayla Livingston, Public Health Policy Advisor, Department of Health
- Daniel Weiss, Professor of Medicine, Professor of Cell and Molecular Biology, University of Vermont
Fiscal notes and materials available on this web page are provided for informational purposes only, and may not comprise all materials received by the Vermont Legislature or the final fiscal information related to a specific bill. The Legislature is not responsible for the accuracy of any information in these materials, and their posting does not constitute approval or endorsement by the Legislature.
No fiscal documents found for S.252 in the Regular Session 2019-2020.
No committee of conference members found for S.252 in the Regular Session 2019-2020.
An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration
Committee of Conference Meetings
Regular Session 2019-2020
| Meeting Date | Committee |
|---|
